ArticleFrontiers in veterinary science2026
Correlation between clinical variables and overall survival time in dogs with multicentric B-cell lymphoma: a retrospective study in Taiwan.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multicentric B-cell lymphoma (MBCL) is one of the most commonly diagnosed spontaneous hematopoietic malignancies in dogs. However, few studies have characterized dogs with MBCL in Taiwan, and the prognostic value of clinical variables, including clinical substage and treatment response, remains under investigation. This study aimed to characterize canine MBCL in Taiwan and evaluate associations between selected clinical variables and overall survival time (OST). Methods: Medical records of 441 dogs diagnosed with lymphoma were retrospectively reviewed. Cases with peripheral lymph node enlargement and uniformly large neoplastic cells on cytology and/or histopathology were included. Immunophenotypes were primarily determined by flow cytometry, with PCR for antigen receptor rearrangement used in a small subset for clonality assessment. Dogs that completed at least one full cycle of CHOP chemotherapy were included in the OST analysis and stratified by clinical variables. Results: Dogs with clinical signs (substage b) had shorter OST (median, 140 days; 95% CI, 126-199) than asymptomatic dogs (substage a: median, 186 days; 95% CI, 164-248). Dogs achieving complete or partial response to CHOP had longer OST (median, 196 days; 95% CI, 151-239) than dogs with stable or progressive disease (median, 182 days; 95% CI, 140-196). No significant differences in OST were observed according to serum calcium concentration (>10.5 mg/dL) or advanced clinical stage (IV-V). Cox proportional hazards analyses indicated that clinical signs (HR, 2.27; 95% CI, 1.04-4.96; Discussion: This study provides the first epidemiological and immunophenotypic characterization of canine MBCL in Taiwan. Clinical substage and initial response to CHOP were associated with OST, although further prospective studies are needed to validate these findings and more comprehensively characterize canine lymphoma in Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.